I-Mab Receives FDA Orphan Drug Designation for its Novel Claudin 18.2 x 4-1BB Bispecific Antibody TJ-CD4B for the Treatment of Gastric Cancer
I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today… Read More »
ReTo Eco-Solutions Subsidiary Selected as a Member of the Hainan Petroleum, Natural Gas and Chemical Industry Federation
ReTo Eco-Solutions, Inc. (NASDAQ: RETO) (“ReTo” or the “Company”), a provider of technology solutions and operation services for intelligent ecological… Read More »
NASA Supported Reality Show ‘Space Hero’ inks Asia Partnership Deal With One Digital Entertainment
The reality show will send a civilian into space for a 6-day mission orbiting Earth and synching with the ISS… Read More »
Claudin18.2 CAR T Cells (CT041) Receives Approval to Initiate A Confirmatory Phase II Clinical Trial for advanced GC/GEJ in China
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of… Read More »
Baidu Launches AI Platform to Enable on-Device, Real-Time Translation from Speech to Hand Gestures
Baidu AI Cloud, a leading AI cloud provider, launched an AI sign language platform able to generate digital avatars for… Read More »
USI Helps Customers Launch Edge AI Computing Servers
The importance of edge computing has become increasingly prominent. USI’s data network storage product line is committed to providing ODM/JDM/EMS… Read More »
Prince Mohammad Bin Fahd University Embraces the Digital Transformation of Higher Education in a World Changed by the COVID-19 Pandemic
Over the last quarter-century, the meteoric rise of the internet and portable electronic devices has swiftly transformed education. Over just… Read More »
Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications
Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or… Read More »
Qiming Venture Partners Welcomes David Chu as IR Partner
Qiming Venture Partners, a leading venture capital firm in China, is pleased to announce that David Chu has joined the… Read More »
Inspiration Capital Partners Completes its Acquisition of Antute
Inspiration Capital Partners (“ICP”) today announced that it has completed its acquisition of Antute (Beijing) Technology Limited (“Antute”), a leading… Read More »